Sanofi stock gains 4.64% as Q3 growth lifts 2026 outlook
Published on 11/07/2026 at 12:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth and pipeline shape outlook
- Sanofi reported strong third-quarter growth led by Dupixent and newer pharmaceutical launches.
- Management raised its 2026 sales and business earnings outlook after the third quarter.
- Research into earlier type 1 diabetes detection adds a longer-term immunoscience angle.
Sanofi stock gained 4.64 percent between the Xetra close on Friday, October 30, and Friday, November 6. The move came during a week in which Sanofi reported double-digit third-quarter growth, raised its 2026 outlook and highlighted work on earlier detection of type 1 diabetes.
Strong quarter supports higher guidance
In its October 30 press release, Sanofi said third-quarter sales rose 14.3 percent at constant exchange rates. Business earnings per share reached 3.55 euros, up 19.6 percent at constant exchange rates.
Dupixent sales increased 34.8 percent to 5.7 billion euros, while sales from pharmaceutical launches rose 31.4 percent to 1.4 billion euros. Vaccine sales declined 6.6 percent to 3.2 billion euros as respiratory prevention demand phased as expected.
Sanofi now expects 2026 sales to grow by a low-teens percentage at constant exchange rates. Business earnings per share are expected to increase by a mid-teens percentage. The upgraded outlook gives investors a higher operating benchmark as the company prepares for Dupixent's eventual loss of exclusivity.
Earlier diabetes detection broadens focus
A November 2 Sanofi article described efforts to identify type 1 diabetes before symptoms emerge. The company said its immunoscience work combines earlier intervention research with screening, monitoring and care pathways.
The initiative is not a near-term earnings measure, but it points to a broader strategy around disease modification and earlier treatment. For investors, the commercial execution in established products remains the immediate operating focus, while research progress could shape the longer-term pipeline.
Sanofi stock traded at 84.34 euros on Lang & Schwarz at 12:11 CET on Saturday, November 7, 0.74 percent above the Xetra close of Friday, November 6.
Sanofi stock facts
- Company: Sanofi S.A.
- ISIN: FR0000120578
- Xetra ticker: SNW
- Lang & Schwarz quote: 84.34 euros on November 7, 2026, at 12:11 CET
- Xetra close: 83.72 euros on November 6, 2026
- Weekly change: 4.64 percent from October 30 to November 6, 2026
For a broader view of the market, see current market reports.
Follow the real-time quote of Sanofi stock for the latest trading reference.
French equities remain linked to the wider direction of the CAC 40, although index moves do not determine Sanofi's company-specific outlook.
